Why It Matters
The House Energy and Commerce Committee hearing scheduled for June 25 will tackle two urgent public health crises: the synthetic opioid epidemic and healthcare affordability. A bill markup hearing on 15 bills reflects Congress's response to emerging drug threats identified in the White House's 2026 National Drug Control Strategy and mounting pressure from seniors struggling with insurance barriers to care.
The White House's 2026 National Drug Control Strategy identifies synthetic opioids such as nitazenes and associated cutting agents like xylazine and medetomidine as being trafficked directly to drug dealers operating within the United States. The strategy also notes that seemingly legitimate commercial operations can directly fuel the nation's drug crisis. Meanwhile, the Centers for Medicare & Medicaid Services (CMS) began enforcing updated hospital price transparency rules on April 1, 2026, creating new compliance obligations that Congress is now examining through legislative action.
The Big Picture
The Drug Scheduling Push
The STOP Nitazenes Act will be among the bills receiving a markup hearing. The bill seeks to permanently schedule nitazene synthetic opioids as Schedule I controlled substances. It covers specific nitazene compounds such as etonitazene and metonitazene, as well as any chemically similar compounds that activate opioid receptors.
A second drug-related bill, the Combating Illicit Xylazine Act, schedules xylazine as Schedule III under the Controlled Substances Act while preserving legitimate veterinary use by allowing veterinarians to prescribe it and pharmacies to dispense it for animal care. The legislation provides a 60-day grace period for practitioner registration and a one-year grace period for labeling and distribution requirements. It also requires the DEA and FDA to report to Congress at 18 months and four years on illicit xylazine prevalence, sources, and related substance risks.
Medicare Prior Authorization and Price Transparency
The Improving Seniors' Timely Access to Care Act of 2025 addresses Medicare prior authorization reform. The bill requires Medicare Advantage plans to publicly disclose which services require prior authorization and report approval and denial rates starting in 2027. It also requires Medicare Advantage plans to adopt a standardized electronic prior authorization system starting in 2028 and directs the Centers for Medicare & Medicaid Services to identify commonly approved services eligible for real-time prior authorization decisions. The bill has 290 listed cosponsors, reflecting bipartisan support.
The Bottom Line
The markup hearing is scheduled for June 25, 2026. The bills being marked up address illicit substances and health care price transparency.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article